These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 10950939

  • 1. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L, Fajkus J, Polácková K, Fulnecek J, Dvoráková D, Krahulcová E.
    Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
    [Abstract] [Full Text] [Related]

  • 2. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
    Sun B, Jiang G, Zaydan MA, La Russa VF, Safah H, Ehrlich M.
    Cancer Res; 2001 Sep 15; 61(18):6931-7. PubMed ID: 11559572
    [Abstract] [Full Text] [Related]

  • 3. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
    Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, Ben-Neriah Y.
    Proc Natl Acad Sci U S A; 1994 Oct 25; 91(22):10722-6. PubMed ID: 7938018
    [Abstract] [Full Text] [Related]

  • 4. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK, Minden MD.
    Biochem Biophys Res Commun; 1997 Apr 28; 233(3):806-12. PubMed ID: 9168938
    [Abstract] [Full Text] [Related]

  • 5. The molecular biology of chronic myeloid leukaemia.
    Melo JV.
    Leukemia; 1996 May 28; 10(5):751-6. PubMed ID: 8656667
    [Abstract] [Full Text] [Related]

  • 6. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK, Minden MD.
    Biochem Biophys Res Commun; 1997 May 29; 234(3):742-7. PubMed ID: 9175786
    [Abstract] [Full Text] [Related]

  • 7. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS, Lee YS, Yun YS, Kim YR, Jeong SS, Lee YK, She CJ, Yoon SS, Shin HR, Kim Y, Cho HI.
    Genes Chromosomes Cancer; 2003 Jul 29; 37(3):291-9. PubMed ID: 12759927
    [Abstract] [Full Text] [Related]

  • 8. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
    Metzke-Heidemann S, Harder L, Gesk S, Schoch R, Jenisch S, Grote W, Siebert R, Schlegelberger B.
    Genes Chromosomes Cancer; 2001 May 29; 31(1):10-4. PubMed ID: 11284030
    [Abstract] [Full Text] [Related]

  • 9. Molecular insights into the Philadelphia translocation.
    Heisterkamp N, Groffen J.
    Hematol Pathol; 1991 May 29; 5(1):1-10. PubMed ID: 2050600
    [Abstract] [Full Text] [Related]

  • 10. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF, Römer J, Starke H, Heller A, Bleck C, Ziegler M, Fiedler W, Liehr T, Clement JH, Claussen U.
    Genes Chromosomes Cancer; 2002 Jun 29; 34(2):193-200. PubMed ID: 11979553
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
    Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV.
    Cancer Res; 2000 Apr 01; 60(7):2049-55. PubMed ID: 10766197
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.
    Reid AG, Tarpey PS, Nacheva EP.
    Genes Chromosomes Cancer; 2003 Jul 01; 37(3):282-90. PubMed ID: 12759926
    [Abstract] [Full Text] [Related]

  • 16. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 17. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein.
    Wada H, Mizutani S, Nishimura J, Usuki Y, Kohsaki M, Komai M, Kaneko H, Sakamoto S, Delia D, Kanamaru A.
    Cancer Res; 1995 Jul 15; 55(14):3192-6. PubMed ID: 7606740
    [Abstract] [Full Text] [Related]

  • 18. Chromatin alterations surrounding the BCR/ABL fusion gene in K562 cells.
    Schaefer-Rego KE, Leibowitz D, Mears JG.
    Oncogene; 1990 Nov 15; 5(11):1669-73. PubMed ID: 2267134
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.
    Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533
    [Abstract] [Full Text] [Related]

  • 20. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV, Gerasimova LP, Sarkisian GP, Borovkova TV, Dukhovenskaia EA, Manakova TE, Naĭdenova NM, Timofeev AM, Grineva NI.
    Tsitologiia; 2007 Dec 12; 49(10):889-900. PubMed ID: 18074781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.